Inquiry Basket
MA-PEG8-VA-PAB-SG3199 is a drug-linker conjugate for ADC by using SG3199 (a PBD dimer,has a potently cytotoxic against cancer cell lines), linked via MA-PEG8-VA-PAB.
| Catalog Number | Size | Price | Quantity | |
|---|---|---|---|---|
| BADC-00741 | -- | $-- | Inquiry |
MA-PEG8-VA-PAB-SG3199, a sophisticated chemical linker molecule, plays a pivotal role in drug development and molecular engineering.
Antibody-Drug Conjugates (ADCs): Serving as a critical linker in ADC development, MA-PEG8-VA-PAB-SG3199 is instrumental in crafting targeted cancer therapies that fuse monoclonal antibodies with cytotoxic drugs. This linker enables the secure attachment of the drug to the antibody, orchestrating a controlled release within cancer cells. It delicately balances stability in circulation with swift release in the tumor microenvironment, enhancing treatment efficacy while mitigating adverse effects.
Controlled-Release Systems: Leveraging the unique chemical properties of MA-PEG8-VA-PAB-SG3199, advanced controlled-release drug delivery systems come to fruition. By incorporating this linker into drug formulations, a prolonged and regulated release of therapeutic agents is achieved. Particularly advantageous for drugs with narrow therapeutic windows, it reduces dosing frequency and enhances patient adherence.
Bioconjugation Studies: Unveiling its versatility, MA-PEG8-VA-PAB-SG3199 emerges as a pivotal tool in bioconjugation methodologies, essential for coupling biomolecules in the study and elucidation of proteins, peptides, and small molecules. Researchers harness this linker to unravel the intricate interactions between diverse biological entities, nurturing the evolution of novel diagnostic assays and therapeutic agents.
Tumor Microenvironment Targeting: Shedding light on cancer research, MA-PEG8-VA-PAB-SG3199 empowers the engineering of drug molecules tailored to target the tumor microenvironment. By fine-tuning its incorporation, novel drug formulations can selectively target specific enzymes or conditions unique to tumor tissues, orchestrating a precise release of therapeutics. This targeted approach enhances the precision of cancer therapies, ensuring minimal harm to healthy tissues while maximizing impact on tumors, reshaping the paradigm of oncological treatment strategies.
Customer Support
Providing excellent 24/7 customer service and support
Project Management
Offering 100% high-quality services at all stages
Quality Assurance
Ensuring the quality and reliability of products or services
Global Delivery
Ensuring timely delivery of products worldwide
BOC Sciences offers comprehensive services for ADC manufacturing, including antibody modification, linker chemistry, payload conjugation, and formulation development. In particular, our payload-linker customization service offers a convenient and fast raw material channel for many ADC researchers.
BOC Sciences provides one-stop site-specific conjugation services for amino acids, glycans, unnatural amino acids, and short peptide tags. In addition, cysteine conjugation, lysine conjugation, enzymatic conjugation, thio-engineered antibody can also be obtained quickly.
BOC Sciences offers a full range of linkers, including peptide linkers, PEG linkers, click chemistry, PROTAC linkers, non-cleavable linkers, etc. We also provide custom development services for chemically labile linkers and enzymatically cleavable linkers.
